Payment overview · 2025
General Payments
$1,616.31
80 reported records · 29 companies
Healthcare provider profile · identity verified
Michael A Schindel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAKEWOOD, CO · NPI 1881778256
Verified facts
What the public records show
CMS Open Payments records show Michael A Schindel, M.D. received $1,616.31 in general payments during 2025 across 80 reported records.
Amgen Inc. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.25 | 12.9% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.07 | 11.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.84 | 10.0% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.77 | 5.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.15 | 5.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.00 | 4.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $63.40 | 3.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.53 | 3.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.85 | 3.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $58.02 | 3.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.58 | 2.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $44.84 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.71 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.08 | 2.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.28 | 2.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $35.45 | 2.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.19 | 2.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.40 | 2.0% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.82 | 2.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.38 | 1.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.17 | 1.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.94 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.89 | 1.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.29 | 1.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $19.92 | 1.2% | 1 | 2025 |
| Vertical Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.76 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.73 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.70 | 1.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.30 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,616.31 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $138.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $128.90 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $117.86 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.78 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $95.77 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.15 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.35 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.00 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $63.40 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.53 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.85 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $58.02 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.84 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.57 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.71 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $35.45 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Relexxii Normalized: relexxii |
Drug | Vertical Pharmaceuticals, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 19 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 121 | 43 |
| Losartan Potassium | Losartan Potassium | 109 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 35 |
| Gabapentin | Gabapentin | 96 | 26 |
| Omeprazole | Omeprazole | 90 | 28 |
| Lisinopril | Lisinopril | 82 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 21 |
| Metformin Hcl Er | Metformin Hcl | 64 | 25 |
| Eliquis | Apixaban | 63 | 18 |
| Finasteride | Finasteride | 62 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 18 |
| Furosemide | Furosemide | 48 | 15 |
| Potassium Chloride | Potassium Chloride | 43 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 12 |
| Azithromycin | Azithromycin | 40 | 33 |
| Tramadol Hcl | Tramadol Hcl | 39 | 11 |
| Allopurinol | Allopurinol | 38 | 17 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 17 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 11 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,616.31 · 80 records | Amgen Inc. | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, Flucelvax, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MINIMED 780G, MOUNJARO, NEXIUM, NEXLETOL, NUZYRA, OTEZLA, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Relexxii, SHINGRIX, SPRAVATO, UBRELVY, UNITHROID, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XHANCE, XIFAXAN, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error